MARKET

NKTR

NKTR

Nektar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.52
+0.07
+0.30%
After Hours: 24.05 +0.53 +2.25% 16:18 07/02 EDT
OPEN
23.76
PREV CLOSE
23.45
HIGH
24.34
LOW
23.45
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
36.85
52 WEEK LOW
13.63
MARKET CAP
4.19B
P/E (TTM)
-8.9792
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NKTR stock price target is 31.21 with a high estimate of 80.00 and a low estimate of 18.00.

EPS

NKTR News

More
Medicenna Company Update And Upcoming Catalysts
Seeking Alpha - Article · 2d ago
Hedge Funds Arent Impressed By Nektar Therapeutics (NKTR)
Insider Monkey · 06/24 02:46
Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/15 02:25
Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?
Zacks · 06/06 16:31
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
PR Newswire · 06/04 22:00
Nektar Therapeutics Highlights Data From Phase 1b Study Of NKTR-358 At European Congress Of Rheumatology
Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being
Benzinga · 06/04 21:02
Nektar Therapeutics to host webcast on NKTR-358 data June 5
Following the virtual presentation of Phase 1b data on candidate NKTR-358 in systemic lupus erythematosus patients at EULAR 2020, Nektar Therapeutics (NASD
seekingalpha · 05/30 21:56
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
PR Newswire · 05/29 22:00

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About NKTR

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
More

Webull offers kinds of Nektar Therapeutics stock information, including NASDAQ:NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.